Invivyd 10-Q: $126.4M Cash, Going-Concern Doubt, Nasdaq Bid Notice
IVVD is trading near its 52-week low of $0.528 (11% above the low).
Summary
Invivyd's Q3 10-Q shows $126.4 million of cash, a $119.3 million nine-month loss and explicit going-concern doubt, alongside a Nasdaq bid-price notice and the June 2027 PEMGARDA EUA termination.
Key Events · Earnings and Guidance · IVVD
-
Going-Concern Doubt Disclosed
Management states that, excluding future external financing, cash will not fund operating expenses and capital requirements beyond one year from issuance of the financial statements.
-
Cash Falls to $126.4M
Cash and cash equivalents were $126.4 million at September 30, 2026, down from $226.7 million at December 31, 2025, after $116.8 million of operating cash burn in the nine months.
-
Q3 Loss Widens to $33.5M
Net loss was $33.5 million, or $0.10 per share, versus $10.5 million a year earlier, as R&D rose to $18.7 million from $8.0 million and SG&A to $30.3 million from $15.0 million.
-
Nasdaq Bid-Price Deadline Looms
A July 23, 2026 Nasdaq notice gives the company until January 19, 2027 to hold a $1.00 closing bid for ten consecutive business days; the stock trades well below that level.
Analysis · IVVD · Life Sciences
The Q3 10-Q formalizes what the morning 8-K flagged and adds the balance-sheet reality: $126.4 million of cash against $116.8 million burned in nine months, with management stating it cannot fund operations beyond one year without new financing. That is a going-concern qualification, and it lands while the company still carries a Nasdaq minimum-bid notice from July 23, 2026 (deadline January 19, 2027) and faces the June 29, 2027 termination of PEMGARDA's EUA, its only revenue source. The bull case rests entirely on the DECLARATION interim analysis, now guided to the fourth quarter of 2026, so the company must bridge to that readout and a potential BLA without running dry. Financing risk is the story here, not the $15.4 million of quarterly PEMGARDA revenue.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVVD was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.6M. The 52-week trading range was $0.53 to $3.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.